[144] Nova Ltd. SEC Filing
Rhea-AI Filing Summary
Form 144 notice for NVMI shows a proposed sale of 2,220 ordinary shares through Oppenheimer & Co. Inc., with an aggregate market value of 526,495.20 and an approximate sale date of 09/03/2025 on Nasdaq. The filing identifies the securities were acquired as Restricted Stock Units on 09/01/2021 (7,000), 09/01/2022 (4,875), 09/01/2023 (2,250) and 09/01/2024 (766). Total outstanding shares listed are 29,278,401. The filer certifies they are not aware of any undisclosed material adverse information and no sales in the past three months are reported.
Positive
- Filing discloses use of a registered broker: Oppenheimer & Co. Inc.
- Acquisition history provided showing securities came from Restricted Stock Units on specific dates
- Filer attests there is no known undisclosed material adverse information
- No securities sold by the filer in the past three months per the form
Negative
- Proposed sale of 2,220 ordinary shares (aggregate market value 526,495.20) is being reported
- The sale will occur against a reported 29,278,401 shares outstanding, which may be considered insider selling activity
Insights
TL;DR Routine insider sale notice: small block relative to outstanding shares, transparent disclosure.
The filing documents a proposed sale of 2,220 ordinary shares via a registered broker with a stated aggregate market value of 526,495.20 and an approximate trade date of 09/03/2025. Acquisition details show these shares originated from Restricted Stock Units granted across 2021–2024. There were no reported sales in the prior three months and the filer attests to no undisclosed material adverse information. For investors, this is a standard compliance disclosure rather than a material corporate event.
TL;DR Proper insider reporting consistent with Rule 144; disclosure and attestations are present.
The form contains the required broker, share count, market value, acquisition dates and nature of acquisition (RSUs). The attestation about material information and indication of no prior three-month sales align with disclosure obligations. The sale size (2,220 shares) should be viewed in the context of reported outstanding shares (29,278,401), and the document itself reflects governance and compliance processes rather than a governance concern.